表紙
市場調査レポート

世界のC型肝炎市場・予測:HCV薬の売上および予測、臨床試験

Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global

発行 Renub Research 商品コード 276657
出版日 ページ情報 英文 87 Pages; 18 Figures; 1 Table
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
世界のC型肝炎市場・予測:HCV薬の売上および予測、臨床試験 Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global
出版日: 2015年08月25日 ページ情報: 英文 87 Pages; 18 Figures; 1 Table
概要

C型肝炎市場は、2012年の市場規模から2018年までに3倍以上に成長すると予測されています。HCV(C型肝炎ウィルス)感染は、慢性感染症の高い罹患率、HCV関連疾患の負担増加、低い検査率および注射薬使用のまん延に関連した発生率増加の見通しなどに特徴付けられた、複雑な公衆衛生問題です。HCV薬市場の成長は主に高いアンメットニーズに起因しており、そのニーズは強いパイプライン候補薬によって満たされると予測されています。

当レポートでは、世界のC型肝炎市について包括的に調査し、市場分析と予測、認可薬の売上と予測、治験段階別のパイプライン薬分析などを提供しており、概略以下の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 C型肝炎薬:市場・予測

第3章 C型肝炎:認可薬の売上・予測

  • Pegasys
  • Pegintron
  • Incivek
  • Victrelis

第4章 C型肝炎:契約・買収

第5章 C型肝炎:パイプライン薬の治験(フェーズ?)

  • Simeprevir (TMC 435) (企業名: Janssen Pharmaceutical)
  • Faldaprevir (BI 201335) (企業名: Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032) (企業名: Bristol-Myers Squibb)
  • Sofosbuvir (PSI-7977 or GS-7977) (企業名: Gilead Sciences)
  • Daclatasvir (BMS-790052) (企業名: Bristol-Myers Squibb)
  • BI-207127 (企業名: Boerhinger Ingelheim)
  • PEG-Interferon Lambda (企業名: Bristol-Myers Squibb)
  • ABT-450/r (Ritonavir) (企業名: Abbott Laboratories)
  • ABT-267 (企業名: Abbott Laboratories)
  • ABT-072/333 (企業名: Abbott Laboratories)
  • Alisporivir (企業名: Novartis)

第6章 C型肝炎:パイプライン薬の治験(フェーズ?)

  • Mericitabine (RG-7128) (企業名: Roche)
  • Danoprevir/r (Ritonavir) (RG7227) (企業名: Roche)
  • GS-9256 (企業名: Gilead Sciences)
  • GS-9451 (企業名: Gilead Sciences)
  • MK-5172 (企業名: Merck)
  • Sovaprevir (ACH-1625) (企業名: Achillion)
  • IDX-320 (企業名: Idenix)
  • MK-8742 (企業名: Merck)
  • ACH-3102 (企業名: Achillion Pharmaceuticals, Inc)
  • IDX-719 (企業名: Idenix)
  • PPI-668 (企業名: Presidio Pharmaceuticals)
  • Setrobuvir (ANA-598) (企業名: Roche)
  • VX-222 (企業名: Vertex Pharmaceuticals)
  • GS-9669 (企業名: Gilead Sciences )
  • GS-9190 (Tegobuvir) (企業名: Gilead Sciences)
  • BMS-791325 (企業名: Bristol-Myers Squibb)

第7章 C型肝炎:パイプライン薬の売上予測

  • Simeprevir (TMC 435)
  • Faldaprevir (BI 201335) (Boerhinger Ingelheim)
  • Asunaprevir (BMS-650032)
  • Sofosbuvir (PSI-7977 or GS-7977)
  • Daclatasvir (BMS-790052)
  • ABT-450/r (Ritonavir)
  • ABT-072/333
  • Alisporivir
  • Mericitabine (RG-7128)
  • Danoprevir (RG7227)
  • GS-9256
  • Setrobuvir (ANA-598)
  • VX-222
  • GS-9190 (Tegobuvir)
  • BMS-791325

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

SUMMARY

Market for Hepatitis C drugs has grown with a phenomenal rate of more than US$ 13 Billion, in the year 2014 compared to 2013. In the last two years a couple of new drugs have been introduced in the market which has become a huge success and they have captured maximum market share of the Hepatitis C market. Gilead currently dominates the multi-billion dollar Hepatitis C market, but AbbVie has been trying to increase its market share since U.S. regulators approved the marketing of its Viekira Pak. Drug makers are already focusing on introducing new drugs in the market as several drugs are standing in the pipeline. Hepatitis C Drugs is anticipated to be a rosy market for future period.

This is 3rd edition report on Hepatitis C Drugs Industry by Renub Research. Report titled “Hepatitis C Market & Forecast, Hepatitis C Pipeline Drugs Sales & Forecast, Clinical Trials - Global” provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 87 page report with 18 Figures and 1 Table studies the Hepatitis C Drug Market Landscape.

  • 1. Hepatitis C Drugs Market & Forecast (Chapter 2)
  • 2. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
  • 3. Hepatitis C - Pipeline Drugs Sales & Forecast (Chapter 4)
  • 4. Hepatitis C Deals & Acquisitions (Chapter 5)
  • 5. Hepatitis C - Company Wise Clinical Trial Analysis (Chapter 6)

Hepatitis C - Approved Drugs Sales & Forecast (To 2020) (Chapter No. 3)

  • 1. Pegasys
  • 2. Pegintron
  • 3. Incivek
  • 4. Victrelis
  • 5. Olysio
  • 6. Sovaldi/Harvoni
  • 7. HCV Franchise
  • 8. Viekira Pak

Hepatitis C - Pipeline Drugs Sales Forecast (To 2020) (Chapter No. 4)

  • 1. Drug A (Merck & Co. Inc.)
  • 2. Drug B (Merck & Co. Inc.)
  • 3. Drug C (Bristol-Myers Squibb)

Hepatitis C - Company Wise Clinical Trial Analysis (Chapter No.5)

  • 1. AbbVie
  • 2. Bristol-Myers Squibb (BMS)
  • 3. Gilead Sciences
  • 4. Merck & Co. Inc.
  • 5. Tibotec/Janssen Therapeutics

DATA SOURCES

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. Hepatitis C Drugs - Market & Forecast

3. Hepatitis C - Approved Drugs Sales & Forecast

  • 3.1. Pegasys Sales & Forecast
  • 3.2. Pegintron Sales & Forecast
  • 3.3. Incivek Sales
  • 3.4. Victrelis Sales & Forecast
  • 3.5. Olysio Sales & Forecast
  • 3.6. Sovaldi / Harvoni Sales & Forecast
  • 3.7. HCV Franchise Sales & Forecast
  • 3.8. Viekira Pak Sales & Forecast

4. Hepatitis C - Pipeline Drugs Sales Forecast

  • 4.1. Drug A of (Merck & Co. Inc.)
  • 4.2. Drug B of (Merck & Co. Inc.)
  • 4.3. Drug C of (Bristol-Myers Squibb)

5. Hepatitis C - Deals & Acquisitions

6. Hepatitis C - Company Wise Clinical Trials Analysis

  • 6.1. AbbVie - Clinical Trials
    • 6.1.1. Phase III
    • 6.1.2. Phase II
    • 6.1.3. Phase I
  • 6.2. Bristol-Myers Squibb (BMS) - Clinical Trials
    • 6.2.1. Phase III
    • 6.2.2. Phase II
  • 6.3. Gilead Sciences - Clinical Trials
    • 6.3.1. Phase II
  • 6.4. Merck & Co. Inc. - Clinical Trials
    • 6.4.1. Phase IV
    • 6.4.2. Phase III
    • 6.4.3. Phase II
    • 6.4.4. Phase I
  • 6.5. Tibotec / Janssen Therapeutics - Clinical Trials
    • 6.5.1. Phase IV
    • 6.5.2. Phase III
    • 6.5.3. Phase II
    • 6.5.4. Phase I

LIST OF FIGURES

  • Figure 2 1: Global - Hepatitis C Drug Market (Million US$), 2010 - 2014
  • Figure 2 2: Global - Forecast for Hepatitis C Drug Market (Million US$), 2015 - 2020
  • Figure 3 1: Global - Pegasys Sales (Million US$), 2005 - 2014
  • Figure 3 2: Global - Forecast for Pegasys Sales (Million US$), 2015 - 2020
  • Figure 3 3: Global - Pegintron Sales (Million US$), 2010 - 2014
  • Figure 3 4: Global - Forecast for Pegintron Sales (Million US$), 2015 - 2020
  • Figure 3 5: Global - Incivek Sales (Million US$), 2011 - 2014
  • Figure 3 6: Global - Victrelis Sales & Forecast (Million US$), 2011 - 2015
  • Figure 3 7: Global - Olysio Sales (Million US$), 2013 - 2014
  • Figure 3 8: Global - Forecast for Olysio Sales (Million US$), 2015 - 2020
  • Figure 3 9: Global - Sovaldi/Harvoni Sales (Million US$), 2013 - 2014
  • Figure 3 10: Global - Forecast for Sovaldi/Harvoni Sales (Million US$), 2015 - 2020
  • Figure 3 11: Global - HCV Franchise Sales & Forecast (Million US$), 2014 - 2020
  • Figure 3 12: Hepatitis C Drugs - Viekira Pak, Sovaldi & Harvoni Initial Prescription (Number), 2013, 2014
  • Figure 3 13: Global - Viekira Pak Sales & Forecast (Million US$), 2014 - 2020
  • Figure 4 1: Global - Forecast for Vaniprevir (MK-7009) Sales (Million US$), 2015 - 2020
  • Figure 4 2: Global - Forecast for Grazoprevir/Elbasvir (MK-5172 + MK-8742) Sales (Million US$), 2016 - 2020
  • Figure 4 3: Global - Forecast for PEG-Interferon Lambda Sales (Million US$), 2015 - 2020

LIST OF TABLES

  • Table 5 1: Hepatitis C - Deals & Acquisitions in the anti-HCV Drug Space, 2004 - 2012
Back to Top